1. Introduction
===============

Schiff bases are a class of compounds with unique biological \[[@B1-molecules-19-08414]\], analytical and industrial properties \[[@B2-molecules-19-08414]\]. A number of Schiff bases have been reported to possess antiglycation \[[@B3-molecules-19-08414],[@B4-molecules-19-08414],[@B5-molecules-19-08414],[@B6-molecules-19-08414]\], antioxidant \[[@B7-molecules-19-08414],[@B8-molecules-19-08414],[@B9-molecules-19-08414],[@B10-molecules-19-08414]\], antileishmanial \[[@B11-molecules-19-08414]\], antifungal \[[@B12-molecules-19-08414]\], anticancer \[[@B13-molecules-19-08414]\], anticonvulscent \[[@B14-molecules-19-08414]\], analgesic \[[@B15-molecules-19-08414]\], antituberclotic \[[@B16-molecules-19-08414]\], and diuretic \[[@B17-molecules-19-08414]\] activities. Heterocyclic Schiff bases with various activities e.g., antibacterial, antifungal and anticancer have also been reported \[[@B18-molecules-19-08414],[@B19-molecules-19-08414],[@B20-molecules-19-08414]\]. The active pharmacophore (-N=CH-) of Schiff bases plays a major role in these significant biological activities. However, the attached neighbouring groups may also affect the activity \[[@B21-molecules-19-08414]\]. Biological activities of Schiff bases metal complexes have also been reported \[[@B22-molecules-19-08414],[@B23-molecules-19-08414]\]. The copper (II) complexes of Schiff bases showed antitumor activity and the lanthanide complexes showed significant antioxidant activity \[[@B24-molecules-19-08414],[@B25-molecules-19-08414],[@B26-molecules-19-08414],[@B27-molecules-19-08414],[@B28-molecules-19-08414]\]. Antioxidants can prevent injury to vessel membranes aiding appropriate blood circulation and are useful for the prevention of cardiovascular diseases. They provide protection against cancer-causing radicals and DNA damages \[[@B29-molecules-19-08414]\]. The action of antioxidants is credited to their ability to convert free radicals to stable molecules. Antioxidants therefore, guard cells from the oxidative damage which leads to aging and diseases \[[@B30-molecules-19-08414],[@B31-molecules-19-08414],[@B32-molecules-19-08414]\]. The free radicals were also reported to play a role in the pathology of arteriosclerosis, malaria and rheumatoid arthritis \[[@B33-molecules-19-08414],[@B34-molecules-19-08414]\].

As for polyphenolic compounds, the phenolic Schiff bases (ArOH) scavenge free radicals (R^•^) by their ability to donate hydrogen atoms from hydroxyl groups through one of the following mechanisms:

(i) Proton Coupled-Electron Transfer (PC-ET) versus Hydrogen atom transfer (HAT)
--------------------------------------------------------------------------------

ArOH + R

•

→ ArO

•

\+ RH

In this mechanism, the electron and proton are transferred from the active phenolic group to the free radical in a single step. This type of reactions can be subdivided into two distinct subclasses, hydrogen atom transfer (HAT) and proton coupled electron transfer (PC-ET) \[[@B35-molecules-19-08414],[@B36-molecules-19-08414],[@B37-molecules-19-08414],[@B38-molecules-19-08414]\]. In HAT, the proton and electron are transferred together, as a hydrogen atom, while in PC-ET mechanism, the proton and electron are transferred between different sets of orbitals \[[@B35-molecules-19-08414]\].

(ii) Electron Transfer-Proton Transfer (ET-PT)
----------------------------------------------

ArOH + R

•

→ArOH

+•

\+ R

−

→ ArO

•

\+ RH

The ET-PT mechanism consists of two steps. In the first step, an electron transfer (ET) from the phenolic compound to the free radical. In the second step, a heterolytic O-H bond dissociation of the radical cation (ArOH^+•^) leads to the formation of a phenoxyl radical (ArOH^•^).

(iii) Sequential Proton Loss Electron Transfer (SPLET)
------------------------------------------------------

ArOH → ArO

−
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\+

ArO

−
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−

R

−
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The above mechanism consists of three steps. In the first step, a heterolytic bond dissociation of a phenolic hydroxyl group leads to the formation of a phenoxyl anion and the release of a proton. In the second step, an electron transfer from the phenoxyl anion to the free radical leads to the formation of a phenoxyl radical and an anion (R^−^). In the end, the protonation of R^−^ leads to the formation of RH. This mechanism is strongly favored under alkaline conditions (e.g., high pH), which may help in the proton of the first step \[[@B39-molecules-19-08414],[@B40-molecules-19-08414]\].

(iv) Adduct formation (AF)
--------------------------

ArOH + R

•

→ \[ArOH-R\]

•

→ stable adducts

The AF mechanism is more specific and is observed between (a) carbon centered radicals and double bonds; or (b) hydroxyl radicals and aromatic rings. Numerous side reactions may occur that lead to stable adducts from \[ArOH-R\]^•^.

In continuation of our research on the synthesis of bioactive small molecules \[[@B41-molecules-19-08414],[@B42-molecules-19-08414],[@B43-molecules-19-08414]\], we synthesized a series of 3,4-dimethoxybenzenamine Schiff bases ([Scheme 1](#molecules-19-08414-f004){ref-type="scheme"}) and evaluated their antioxidant potential in the search of the potential antioxidant leads.

![Synthesis of 3,4-dimethoxybenzenamine Schiff bases.](molecules-19-08414-g004){#molecules-19-08414-f004}

2. Results and Discussion
=========================

2.1. Chemistry
--------------

The 3,4-dimethoxybenzenamine Schiff bases were prepared by condensing 3,4-dimethoxy-benzenamine with several aromatic aldehydes by refluxing in ethanol for 3 to 4 h ([Scheme 1](#molecules-19-08414-f004){ref-type="scheme"}). The crude products were further recrystallized from methanol and in most of the cases needle-like crystals were obtained (yields 81%--92%). The structural confirmation of the dimethoxybenzenamine Schiff bases was done by various spectroscopic techniques including ^1^H-NMR, IR and mass spectroscopy. All synthetic compounds were established as having *E* configuration \[[@B44-molecules-19-08414],[@B45-molecules-19-08414],[@B46-molecules-19-08414]\]. The compounds **8**, **9**, **10**, **15**, **22**, **24** and **25** are known \[[@B47-molecules-19-08414],[@B48-molecules-19-08414],[@B49-molecules-19-08414],[@B50-molecules-19-08414]\] but compound **13** has only a CAS registry number 1002275--90--2 with no reference. Compounds **1--7**, **11**, **12**, **14**, **16**, **18--21**, **23** are new.

2.2. Antioxidant Activities
---------------------------

### 2.2.1. DPPH Scavenging Activity

The synthesized compounds **1--25** showed activity in the range of 10.12--84.34 μM ([Table 1](#molecules-19-08414-t001){ref-type="table"}). Compound **1** (IC~50~ = 10.12 ± 0.54 μM) showed highest activity, three times more active than the standard (IC~50~ = 30.30 ± 0.2 μM). This is due to the *ortho*-trihydroxyl group which is known to show very good activity \[[@B51-molecules-19-08414],[@B52-molecules-19-08414]\]. Compound **2** is a *meta*-trihydroxyl analogue but showed slightly less activity than compound **1**. This may be due to the *ortho*-trihydroxyl groups of compound **1** which is similar to the catecholic moeity known to exhibit good antioxidant activities \[[@B53-molecules-19-08414],[@B54-molecules-19-08414],[@B55-molecules-19-08414],[@B56-molecules-19-08414]\].

molecules-19-08414-t001_Table 1

###### 

*In vitro* DPPH activity and % yield of compounds **1--25**.

  N°       Yield (%)   IC~50~ (μM ± SEM ^a^)   N°                       Yield (%)   IC~50~ (μM ± SEM ^a^)
  -------- ----------- ----------------------- ------------------------ ----------- -----------------------
  **1**    84          10.12 ± 0.54            **14**                   87          42.80 ± 2.80
  **2**    82          15.6 ± 0.06             **15**                   82          NA ^b^
  **3**    78          19.2 ± 0.70             **16**                   82          NA ^b^
  **4**    84          28.14 ± 0.86            **17**                   84          NA ^b^
  **5**    85          30.45 ± 0.82            **18**                   83          NA ^b^
  **6**    86          28.10 ± 1.30            **19**                   85          NA ^b^
  **7**    81          33.02 ± 1.20            **20**                   87          NA ^b^
  **8**    83          34.14 ± 1.50            **21**                   88          NA ^b^
  **9**    92          40.01 ± 1.80            **22**                   \-          NA ^b^
  **10**   88          NA ^b^                  **23**                   90          NA ^b^
  **11**   90          50.01 ± 2.20            **24**                   84          NA ^b^
  **12**   87          38.16 ± 2.10            **25**                   92          NA ^b^
  **13**   90          NA ^b^                  *n*-propyl gallate ^c^   \-          30.30 ± 0.2

SEM ^a^ is the standard error of the mean, NA ^b^ = Not active, *n*-propyl gallate ^c^ was the standard drug for the DPPH assays.

Incidently, compounds **1** and **2** which have an additional hydroxyl group as compared to compounds **4** and **6**, showed stronger antioxidant activities than the latter two compounds. Among the five dihydroxyl analogues, compound **3**, **4** and **6** showed better activity than standard. The activity of compound **3** is due to the 2\', 5\' positions of the dihydroxyl groups, favorable for stabilization of the free radical. The catecholic moeity in compounds **4** and **6** is well known structural feature for good activity \[[@B53-molecules-19-08414],[@B54-molecules-19-08414],[@B55-molecules-19-08414],[@B56-molecules-19-08414]\]. Other *meta*-dihydroxyl analogues **5** and **7** also showed very close activity as compared to the standard. Compound **8** showed good activity due to adjacent 3-methoxyl and 4-hydroxyl positions. However, its other analogue **11** with reversed arrangement showed moderate activity.

For the mono-hydroxyl series, compound **9** having hydroxyl at 4\' position showed good activity while its other analogues **10** and **15** showed no activity, due to the lack of free radical stabilizing capability. The presence of a bromo substituent further increases the capability to stabilize radicals as illustrated by compound **12**. *meta*-arranged methoxyl and hydroxyl groups contributed to the good activity of compound **14**. The remaining compounds do not possess functional groups to help stabilize free radicals and are therefore inactive.

### 2.2.2. Superoxide Scavenging Activity

Compounds **1**, **2** and **3** showed better activity than the standard drug *n*-propylgallate ([Table 2](#molecules-19-08414-t002){ref-type="table"}). Compound 4 showed good activity. Compounds **5**, **6**, **7**, **8**, **9** and **12** showed moderate activities, while compound **14**, **20** and **21** showed weak activities. The good activity of compounds **1--3** may be due to more stabilizing potential of these compounds to stabilize free radicals generated during bioassay. DPPH scavenging activity and superoxide scavenging activity mainly depend on the hydroxyl position as well as number of hydroxyl groups present in the molecule \[[@B57-molecules-19-08414],[@B58-molecules-19-08414]\].

molecules-19-08414-t002_Table 2

###### 

*In vitro* superoxide anion radical scavenging activity of compounds **1--25**.

  Comp. No.   IC~50~ (μM ± SEM ^a^)   Comp. No                 IC~50~ (μM ± SEM ^a^)
  ----------- ----------------------- ------------------------ -----------------------
  **1**       85.03 ± 1.20            **14**                   260.3 ± 6.4
  **2**       90.60 ± 1.50            **15**                   NA ^b^
  **3**       98.60 ± 1.70            **16**                   NA ^b^
  **4**       145 ± 2.1               **17**                   NA ^b^
  **5**       170.2 ± 3.2             **18**                   NA ^b^
  **6**       175.0 ± 3.5             **19**                   NA ^b^
  **7**       180.1 ± 3.8             **20**                   315.1 ± 8.4
  **8**       190.1 ± 3.9             **21**                   320.1 ± 6.3
  **9**       208.9 ± 5.4             **22**                   NA ^b^
  **10**      NA ^b^                  **23**                   NA ^b^
  **11**      NA ^b^                  **24**                   NA ^b^
  **12**      210.1 ± 4.4             **25**                   NA ^b^
  **13**      NA ^b^                  *n*-propyl gallate ^c^   106.34 ± 1.6

SEM ^a^ is the standard error of the mean, NA ^b^ = Not active, *n*-propyl gallate ^c^ was the standard drug for the superoxide anionradical scavenging assays.

2.3. X-ray Crystallography Studies
----------------------------------

### 2.3.1. Compound **13**

The structure of compound **13** is composed of a dimethoxybenzene moiety link with methoxyphenol moiety via azomethin bridge which adopts an *E* configuration ([Figure 1](#molecules-19-08414-f001){ref-type="fig"}). The dimethoxy-substituted planar benzene moiety (C1-C6) is oriented at a dihedral angle of 29.33(9)° with respect to the methoxy-substituted planar phenol moiety (C1\'--C6\') with standard deviation of 0.016(2)° for C2\' atom from root mean square plane. In the crystal lattice ([Figure 2](#molecules-19-08414-f002){ref-type="fig"}), molecules are linked via C--H···O hydrogen bonding and form three dimensional consolidated network of mirror imaged sets running along the *b* axis where each set contains four molecule.

![X-ray and optimized structures of compounds **13**, **15** and **16**.](molecules-19-08414-g001){#molecules-19-08414-f001}

![Crystal packing diagram for compounds **13**, **15** and **16**.](molecules-19-08414-g002){#molecules-19-08414-f002}

Crystallographic data of compound **13** (CCDC 980015), can be obtained from Cambridge Crystallographic Data Center without any cost. Crystal and experimental data of compound **13** are presented in [Table 3](#molecules-19-08414-t003){ref-type="table"} and the hydrogen bonding data in [Table 4](#molecules-19-08414-t004){ref-type="table"}.

molecules-19-08414-t003_Table 3

###### 

The crystal X-ray and experimental data of compounds **13**, **15** and **16**.

                           Compound 13             Compound 15             Compound 16
  ------------------------ ----------------------- ----------------------- -----------------------
  Empirical formula        C~16~H~17~NO~4~         C~15~H~15~NO~3~         C~17~H~19~NO~4~
  Formula weight           287.31                  257.28                  301.33
  Temperature              273(2)K                 273(2)K                 273(2)K
  Wavelength               0.71073 Å               0.71073 Å               0.71073 Å
  Crystal system           Orthorhombic            Orthorhombic            Monoclinic
  Space group              Pna2(1)                 P2(1)2(1)2(1)           P2(1)/c
  a                        9.7203(7) Å             5.3625(2)Å              11.1898(4) Å
  b                        30.576(2) Å             11.1755(5) Å            17.5567(6) Å
  c                        4.8328(3) Å             21.9532(10)Å            8.1013(3) Å
  *α*                      90°                     90°                     90°
  *β*                      90°                     90°                     98.0720(10)°
  *γ*                      90°                     90°                     90°
  Volume                   1436.36(17)A^3^         1315.63(10)A^3^         1575.78(10) A^3^
  Z                        4                       4                       4
  Calculated density       1.329 mg/m^3^           1.299 mg/m^3^           1.270 mg/m^3^
  Absorption coefficient   0.096 mm^−1^            0.091 mm^−1^            0.091 mm^−1^
  F(000)                   608                     544                     640
  Crystal size             0.67 × 0.16 × 0.14 mm   0.77 × 0.49 × 0.45 mm   0.46 × 0.44 × 0.42 mm
  θ range                  1.33 to 25.50 °         1.86 to 25.50°          1.84 to 25.50
  Reflections Collected    8206                    7839                    9213
  Reflections Unique       2629                    2426                    2934
  (*R*~int~)               0.0216                  0.0165                  0.0148
  *R*~1~ with I \> 2σ(I)   0.0347                  0.0369                  0.0352
  *R*~2~ with I \> 2σ(I)   0.0808                  0.1066                  0.0967
  *R*~1~ for all data      0.0412                  0.0386                  0.0399
  *R*~2~ for all data      0.0855                  0.1086                  0.1012
  Goodness of fit          1.059                   1.091                   1.046
  max/min *ρ* eA°^−3^      0.107 and −0.129        0.349 and −0.295        0.140 and −0.141
  CCDC number              CCDC 980015             CCDC 980014             CCDC 980016
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###### 

Hydrogen bonding data for compound 13.

  D      H       A        D-H       H\...A    D\...A     D-H...A
  ------ ------- -------- --------- --------- ---------- ---------
  O1\'   H1A\'   N7       0.94(3)   1.78(3)   2.628(2)   149(2)
  C5     H5A     O2 ^a^   0.93      2.53      3.319(2)   143

Symmetry codes: ^a^ 1/2+x,1/2-y,z.

### 2.3.2. Compound **15**

Structurally, compound **15** is similar to compound **13** with the difference that the planar phenyl ring (C1\'-C6\') has only one hydroxyl group at the C3\' position. The dihedral angle between the two planar benzene ring (C1\'-C6\' and C1-C6) was found to be 44.35(7)° with standard deviation of 0.009(2)° for C5 atom from root mean square plane.

The molecule does not possess any intramolecular interactions in the crystal lattice, molecules are packed in a series and form a consolidated network running along *c*-axis, joining through intermolecular O1\-\--H1A\'\...N7, C6\-\--H6\'A\...O2, C5\-\--H5A\...O1 hydrogen bonds. Crystallographic data of compound **15** (CCDC 980014), can be obtained from Cambridge Crystallographic Data Center without any cost. Crystal and experimental data of compound 15 presented in [Table 3](#molecules-19-08414-t003){ref-type="table"} and hydrogen bonding data in [Table 5](#molecules-19-08414-t005){ref-type="table"}.

molecules-19-08414-t005_Table 5

###### 

Hydrogen bonding data for compound **15**.

  D      H       A        D-H         H\...A      D\...A       D-H...A
  ------ ------- -------- ----------- ----------- ------------ -----------
  O1\'   H1A\'   N7 ^a^   0.939(18)   1.891(18)   2.7841(16)   158.1(16)
  C6\'   H6\'A   O2 ^b^   0.93        2.58        3.2572(17)   130
  C5     H5A     O1 ^c^   0.93        2.57        3.1655(18)   123

Symmetry codes: ^a^ 1/2+x,1/2-y,-z ; ^b^ 1-x,1/2+y,1/2-z; ^c^ -3/2+x,1/2-y,-z.

### 2.3.3. Compound **16**

Compound **16** is structurally similar to Compound **13** and Compound **15** with the only difference that all four substituents on the aromatic skeleton are methoxyl groups. In this molecule the two benzene rings and the azomethine group are practically coplanar and the molecule adopts an *E* configuration about the C8-N7 bond. The dihedral angle between the two planar benzene rings (C1\'-C6\' and C1-C6) was found to be 40.56(6)° with standard deviation of −0.019(1)° for C1 atom from root mean square plane. All the bond distances are within normal range comparable to those of similar compounds. No chemical intramolecular interaction was observed. However in the crystal structure, molecules were linked via C2-H2\'A\...O1 and C3-H3A\...O1 intermolecular interactions to form R^2^~2~ (20) ring motive running along c-axis.

The crystallographic data of compound **16** (CCDC 980016), can be obtained from Cambridge Crystallographic Data Center. Crystal and experimental data of compound **16** presented in [Table 3](#molecules-19-08414-t003){ref-type="table"} and hydrogen bonding data in [Table 6](#molecules-19-08414-t006){ref-type="table"}.

molecules-19-08414-t006_Table 6

###### 

Hydrogen bonding data for compound **16**.

  D    H      A         D-H    H\...A   D\...A       D-H...A
  ---- ------ --------- ------ -------- ------------ ---------
  C2   H2'A   O1 ^a.^   0.93   2.57     3.4945(16)   176
  C3   H3A    O1 ^b^    0.93   2.52     3.4418(16)   170

Symmetry codes: ^a^ 1-x,-y,2-z; ^b^ x,1/2-y,-1/2+z.

2.4. DFT Calculations
---------------------

Crystal structures of compounds **13**, **15** and **16** were compared to their optimized minima ([Figure 3](#molecules-19-08414-f003){ref-type="fig"}). The initial geometrical structures were obtained from the molden files of the X-ray solved structures. The optimization has been carried out at the B3LYP/6-311+G(d,p) level of theory by using Gaussian 09 package \[[@B7-molecules-19-08414]\].

![Optimized structures of compounds **1**, **2**, **3**, **8** and **18**.](molecules-19-08414-g003){#molecules-19-08414-f003}

The minima of the optimized structures were confirmed by the absence of imaginary frequencies. The experimental and calculated bond lengths, bond and dihedral angles of the compounds are presented in [Table 7](#molecules-19-08414-t007){ref-type="table"}.
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###### 

The calculated and experimental values of the bond lengths, bond angles and torsion angles of compounds **13**, **15**, and **16**.

                           13     15        16     Calculated                                                
  ------------------------ ------ --------- ------ ------------ ------ --------- ------ ------ ------ ------ ------
  **Bond lengths (Å)**                                                                                       
  C1-N7                    1.41   1.413     1.40   1.4243       1.41   1.4181    1.40   1.41   1.41   1.40   1.41
  N7-C8                    1.29   1.276     1.28   1.2673       1.28   1.2677    1.28   1.29   1.29   1.27   1.28
  C8-C1\'                  1.45   1.452     1.47   1.4680       1.47   1.4650    1.47   1.44   1.45   1.46   1.47
  C2\'-O2\'                1.34   1.358     \-     \-           \-     \-        \-     1.37   1.35   \-     \-
  C3\'-O3\'                1.37   \-        1.37   1.3601       1.36   1.3673    1.36   \-     \-     1.37   1.36
  C5\'-O4\'                \-     \-        \-     \-           \-     \-        1.37   1.36   \-     1.36   \-
  C5\'-O5\'                1.37   1.382     \-     \-           1.37   1.3694    1.38   \-     1.37   \-     \-
  C6\'-O6\'                \-     \-        \-     \-           \-     \-        \-     1.34   \-     \-     \-
  **Bond angles (°)**                                                                                        
  C2-C1-N7                 125    123.31    126    122.15       126    122.79    123    123    123    123    123
  C1-N7-C8                 124    121.07    123    119.72       123    118.20    121    122    122    120    121
  N7-C8-C1'                122    122.43    122    123.96       123    124.02    123    122    122    123    123
  **Torsion angles (°)**                                                                                     
  C2-C1-N7-C8              0      −155.52   0      −43.09       0      34.70     37     32     34     36     30
  C1-N7-C8-C1\'            −180   −175.32   −180   174.26       −180   −179.25   −177   −177   −177   −177   −177
  N7-C8-C1\'-C2'           0      0         0      −1.1         0      −174.83   2      0      1      1      1

The experimental bond lengths and bond angles z-matrix coordinates are well reproduced theoretically. On the other hand, the dihedral angles are well reproduced, except for the dihedral angle between the 3,4-dimethoxybenzenyl and the azo group where a slight deviation was observed between the crystal structure compared to the optimized conformation. The hydrogen bonding between 2\'-OH group and the azo group in Compound **13** is well reproduced theoretically, with a difference of 0.04 Å ([Figure 1](#molecules-19-08414-f001){ref-type="fig"}). In order to generalize the comparison between structural X-ray and calculated results, the optimized structures of compounds **1**, **2**, **3**, **8** and **18** were obtained at the same level of theory ([Table 7](#molecules-19-08414-t007){ref-type="table"} and [Figure 3](#molecules-19-08414-f003){ref-type="fig"}). The structural parameters (bond, angles, and torsion angles) for the optimized structures of **1**, **2**, **3**, **8** and **18** are very similar to the optimized and X-ray parameters of **13**, **15** and **16**.

3. Experimental
===============

3.1. General Information
------------------------

NMR experiments were performed in DMSO-*d~6~* on a Bruker Ultra Shield 500 MHz FT NMR (Wissembourg, Switzerland). CHN analysis was performed on a Carlo Erba Strumentazione-Mod-1106 (Milan, Italy). Electron impact mass spectra (EI-MS) were recorded on a Finnigan MAT-311A instrument (Bremen, Germany). Thin layer chromatography (TLC) was performed on pre-coated silica gel aluminum plates (Kieselgel 60, 254, E. Merck, Darmstadt, Germany). Chromatograms were visualized by UV at 254 and 365 nm.

3.2. DPPH (1,1-Diphenyl-2-picryl hydrazyl) Free Radical Scavenging Activity
---------------------------------------------------------------------------

The free radical scavenging activity was measured by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay using literature protocols. The reaction mixture contained test sample (5 μL, 1 mM in DMSO) and DPPH (Sigma, 95 μL, 300 μM) in ethanol. The reaction mixture was taken into a 96-well microtiter plate and incubated at 37 °C for 30 min. The absorbance was measured at 515 nm using microtitre plate reader (Molecular Devices, Sunnyvale, CA, USA). Percent radical scavenging activity was determined in comparison with DMSO containing control ([Table 1](#molecules-19-08414-t001){ref-type="table"}). IC~50~ values represent the concentration of compounds able to scavenge 50% of DPPH radicals. Propyl gallate was used as positive control. All chemicals used were of analytical grade (Sigma, Ronkonkoma, NY, USA).

3.3. In Vitro Assay for Superoxide Anion Radical Scavenging Activity
--------------------------------------------------------------------

The superoxide producing system was set up by mixing phenazinemethosulfate (PMS), NADH, and oxygen (air), and the production of superoxide was estimated by the nitroblue tetrazolium method. Measurement of superoxide radical scavenging activity was carried out on the basis of the method described by the modified method used by Ferda. In aerobic reaction mixtures containing NADH, phenazine methosulphate and nitro blue tetrazolium, PMS is reduced by NADH and then gave rise to O~2~^−^, which in turn reduced NBT. On the basis of this PMS has frequently been used to mediate O~2~^−^.

The reaction mixture comprised 100 µM β-nicotinamide adenine dinucleotide reduced form (NADH, 40 µL), 80 µM of nitro blue tetrazolium (NBT, 40 µL), 8 µM phenazine methosulphate (PMS, 20 µL), 1 mM sample (10 µL), and 0.1 M phosphate buffer (pH 7.4, 90 µL). The reagents were prepared in buffer and sample in DMSO. The reaction was performed in 96-well microtitre plate at room temperature and absorbance was measured at 560 nm. The formation of superoxide was monitored by measuring the formation of water soluble blue formosan dye. A lower absorbance of reaction mixture indicated a higher scavenging activity of the sample. Percent radical scavenging activity (% RSA) by samples was determined in comparison with a control using the following equation:

%RSA = 100 − {(OD test compound/OD control) × 100

3.4. General Procedure for the Synthesis 3,4-Dimethoxybenzenamine Schiff Bases
------------------------------------------------------------------------------

The 3,4-dimethoxyanaline Schiff bases were synthesized by refluxing in ethanol (10 mL) for 3 h 3,4-dimethoxyanaline (2 mmol) and each pure aryl aldehyde (2 mmol). The progress of the reaction was monitored by TLC. After completion of reaction, the solvent was evaporated under vacuum to afford crude products which were further recrystallized from methanol to give needle-like pure products in good to excellent yields.

*(E)-5-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,2,3-triol* (**1**). ^1^H-NMR: *δ* 11.05 (s, 2H, OH), 9.61 (s, 1H, OH), 8.60 (s, 1H, N=CH-Ar), 7.05 (s, 2H), 6.95 (d, 1H, *J* = 8.0 Hz), 6.91 (d, 1H, *J* = 2.0 Hz), 6.82 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 3.83 (s, 3H, OCH~3~), 3.77 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 150.1, 148.1, 146.3, 146.2, 146.2, 138.1, 134.2, 119.4, 114.2, 109.2, 108.8, 108.8, 56.3, 56.3; Anal. Calcd for C~15~H~15~NO~5~, C = 62.28, H = 5.23, N = 4.84 Found C = 62.29, H = 5.22, N = 4.85 EI MS *m/z* (% rel. abund.): 289 (M^+^, 10), 258 (12), 138 (20), 137 (100).

*(E)-2-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,3,5-triol* (**2**). ^1^H-NMR: *δ* 10.65 (s, 2H, OH), 9.23 (s, 1H, OH), 8.65 (s, 1H, N=CH-Ar), 7.15 (s, 2H), 6.94 (d, 1H, *J* = 8.0 Hz), 6.90 (d, 1H, *J* = 2.0 Hz), 6.81 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.82 (s, 3H, OCH~3~), 3.79 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 163.7, 163.7, 163.4, 160.1, 146.4, 150.2, 148.1, 119.4, 114.3, 109.2, 106.1, 96.2, 96.2, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~5~, C = 62.28, H = 5.23, N = 4.84, Found C = 62.28, H = 5.23, N = 4.84; EI MS *m/z* (% rel. abund.): 289 (M^+^, 13), 258 (11), 138 (17), 137 (100).

*(E)-2-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,4-diol* (**3**). ^1^H-NMR: *δ* 12.49 (s, 1H, OH), 10.18 (s, 1H, OH), 9.19 (s, 1H, N=CH-Ar), 7.11 (d, 1H, *J* = 7.0 Hz), 7.04 (s, 1H), 7.00 (d, 1H, *J* = 7.0 Hz), 6.97 (d, 1H, *J*~3/2~ = 8.0 Hz), 6.86 (d, 1H, *J* = 8.0, Hz), 6.78 (s, 1H), 3.80 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.0, 153.6, 151.0, 150.1, 148.7, 146.3, 120.3, 119.4, 119.5, 118.4, 116.1, 114.2, 109.2, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~4~, C = 65.92, H = 5.53, N = 5.13, Found C = 65.91, H = 5.54, N = 5.12; EI MS *m/z* (% rel. abund.): 273 (M^+^, 60), 241 (8), 137 (100), 122 (20), 109 (30).

*(E)-4-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,2-diol* (**4**). ^1^H-NMR: *δ* 12.20(s, 1H, OH), 10.30 (s, 1H, OH), 8.40 (s, 1H, N=CH-Ar), 7.10 (d, 1H, *J* = 7.0 Hz), 7.06 (s, 1H), 7.02 (d, 1H, *J* = 7.0 Hz), 6.88 (d, 1H, *J*~3/2~ = 8.0 Hz), 6.82 (d, 1H, *J* = 8.0, Hz), 6.74 (s, 1H), 3.83 (s, 3H, OCH~3~), 3.79 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 149.4, 146.2, 117.1, 116.1, 131.1, 123.1, 160.2, 146.4, 109.1, 114.2, 119.1, 148.1, 150.0, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~4~, C = 65.92, H = 5.53, N = 5.13, Found C = 65.90, H = 5.55, N = 5.11; EI MS *m/z* (% rel. abund.): 273 (M^+^, 42), 241 (12), 137 (100), 122 (15), 109 (28).

*(E)-4-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,3-diol* (**5**). ^1^H-NMR: *δ* 13.71 (s, 1H, OH), 10.18 (s, 1H, OH), 8.80 (s, 1H, N=CH-Ar), 7.40 (d, 1H, *J* = 8.0 Hz), 7.05 (d, 1H, *J* = 2.0 Hz), 6.99 (d, 1H, *J* = 7.0 Hz), 6.92 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 6.40 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 6.28 (d, 1H, *J* = 2.0 Hz),3.82 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 162.3, 162.1, 160.1, 150.2, 148.1, 146.4, 133.6, 119.4, 114.2, 113.0, 109.1, 108.5, 103.5, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~4~, C = 65.92, H = 5.53, N = 5.13 Found C = 65.93, H = 5.55, N = 5.12; EI MS *m/z* (% rel. abund.): 273 (M^+^, 70), 241 (17), 137 (100), 122 (22), 109 (38).

*(E)-3-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,2-diol* (**6**). ^1^H-NMR: *δ* 13.42 (s, 1H, OH), 9.11 (s, 1H, OH), 8.93 (s, 1H, N=CH-Ar), 7.72 (d, 1H, *J* = 8.0 Hz), 7.15 (d, 1H, *J* = 8.0 Hz), 7.10 (s, 1H), 7.07 (d, 1H, *J* = 2.0 Hz), 6.76 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 7.65 (t, 1H, *J* = 8.0 Hz), 3.81 (s, 3H, OCH~3~), 3.79 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 151.5, 150.1, 148.2, 146.4, 146.0, 124.6, 122.7, 119.8, 119.6, 119.5, 114.2, 109.1, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~4~, C = 65.92, H = 5.53, N = 5.13, Found C = 65.91, H = 5.54, N = 5.12; EI MS *m/z* (% rel. abund.): 273 (M^+^, 78), 241 (16), 137 (100), 122 (11).

*(E)-5-(((3,4-Dimethoxyphenyl)imino)methyl)benzene-1,3-diol* (**7**). ^1^H-NMR: *δ* 9.47 (s, 2H, 2×OH), 8.45 (s, 1H, N=CH-Ar), 7.01 (d, 2H, *J* = 8.0 Hz), 6.84 (d, 1H, *J* = 2.0 Hz), 6.65 (d, 1H, *J* = 8.0 Hz), 6.40 (d, 1H, *J* = 2.0 Hz), 6.06 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 3.81 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 160.1, 160.0, 150.1, 148.1, 146.4, 141.3, 119.5, 114.3, 109.1, 107.4, 107.4, 105.8, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~4~, C = 65.92, H = 5.53, N = 5.13, Found C = 65.92, H = 5.54, N = 5.11; EI MS *m/z* (% rel. abund.): 273 (M^+^, 50), 241 (11), 137 (100), 122 (18).

*(E)-4-(((3,4-Dimethoxyphenyl)imino)methyl)-2-methoxyphenol* (**8**). ^1^H-NMR: *δ* 9.65 (s, 1H, OH), 8.49 (s, 1H, N=CH-Ar), 7.51 (d, 1H, *J* = 2.0 Hz), 7.32 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 6.96 (d, 1H, *J* = 8.0 Hz), 6.93 (d, 1H, *J* = 2.0 Hz), 6.89 (d, 1H, *J* = 8.0 Hz), 6.06 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.85 (s, 3H, OCH~3~), 3.81 (s, 3H, OCH~3~), 3.76 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 151.1, 150.1, 149.1, 148.2, 146.3, 130.8, 122.8, 119.5, 117.1, 114.2, 112.0, 109.1, 56.1, 56.1, 55.9; Anal. Calcd for C~16~H~17~NO~4~, C = 66.89, H = 5.96, N = 4.88, Found C = 65.90, H = 5.95, N = 4.90; EI MS *m/z* (% rel. abund.): 287 (M^+^, 100), 255 (13), 137 (84), 122 (25).

*(E)-4-(((3,4-Dimethoxyphenyl)imino)methyl)phenol* (**9**). ^1^H-NMR: *δ* 10.04 (s, 1H, OH), 8.50 (s, 1H, N=CH-Ar), 7.77 (d, 2H, *J* = 8.0 Hz), 6.96 (d, 1H, *J* = 8.0 Hz), 6.92 (d, 1H, *J* = 2.0 Hz), 6.88 (d, 2H, *J* = 8.0 Hz), 6.81 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 3.80 (s, 3H, OCH~3~), 3.76 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.5, 160.0, 150.0, 148.1, 146.4, 130.4, 130.4, 129.2, 119.4, 116.0, 116.0, 114.2, 109.1, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~3~, C = 70.02, H = 5.88, N = 5.44, Found C = 70.01, H = 5.89, N = 5.43; EI MS *m/z* (% rel. abund.): 257 (M^+^, 100), 225 (11), 137 (68), 105 (20).

*(E)-2-(((3,4-Dimethoxyphenyl)imino)methyl)phenol* (**10**). ^1^H-NMR: *δ* 13.32 (s, 1H, OH), 8.93 (s, 1H, N=CH-Ar), 7.63 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), (dt, 1H, *J* = 8.0, *J* = 2.0 Hz), 6.93 (d, 1H, *J* = 2.0 Hz), 6.80-6.72 (m, 4H), 3.83 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 161.1, 160.0, 150.1, 148.1, 146.4, 132.2, 132.0, 121.3, 120.4, 119.4, 117.6, 114.2, 109.1, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~3~, C = 70.02, H = 5.88, N = 5.44, Found C = 70.03, H = 5.88, N = 5.43; EI MS *m/z* (% rel. abund.): 257 (M^+^, 100), 225 (15), 137 (80), 93 (30).

*(E)-5-(((3,4-Dimethoxyphenyl)imino)methyl)-2-methoxyphenol* (**11**). ^1^H-NMR: *δ* 9.28 (s, 1H, OH), 8.48 (s, 1H, N=CH-Ar), 7.42 (d, 1H, *J* = 2.0 Hz), 7.30 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 7.04 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 1H, *J* = 8.0 Hz), 6.93 (d, 1H, *J* = 2.0 Hz), 6.82 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 3.84 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~), 3.77 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.0, 152.1, 150.1, 148.2, 147.2, 146.4, 147.1, 131.0, 125.4, 119.4, 115.8, 114.2, 109.1, 56.1, 56.1, 55.8; Anal. Calcd for C~16~H~17~NO~4~, C = 66.89, H = 5.96, N = 4.88, Found C = 66.88, H = 5.95, N = 4.89; EI MS *m/z* (% rel. abund.): 287 (M^+^, 100), 255 (18), 137 (69), 122 (20).

*(E)-2-Bromo-4-(((3,4-dimethoxyphenyl)imino)methyl)phenol* (**12**). ^1^H-NMR): *δ* 12.68 (s, 1H, OH), 8.94 (s, 1H, N=CH-Ar), 8.04 (d, 1H, *J* = 2.0 Hz), 7.76 (dd, 1H, *J* = 8.0, *J* = 2.0, Hz), 7.07 (d, 1H, *J* = 8.0 Hz), 6.98 (d, 1H, *J* = 8.0 Hz), 6.95 (d, 1H, *J* = 2.0 Hz), 6.84 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.80 (s, 3H, OCH~3~), 3.77 (s, 3H, OCH~3~); ^13^C-NMR (DMSO-*d~6~*): *δ* 160.1, 158.6, 150.1, 148.2, 146.4, 130.2, 129.5, 128.4, 119.5, 118.1, 114.3, 113.8, 109.2, 56.1, 56.1; Anal. Calcd for C~15~H~14~BrNO~3~, C = 53.59, H = 4.20, N = 4.17, Found C = 53.60, H = 4.21, N = 4.18; EI MS *m/z* (% rel. abund.): 337 (M+2 , 61), 335 (M^+^ , 64), 255 (30), 137 (100).

*(E)-2-(((3,4-Dimethoxyphenyl)imino)methyl)-4-methoxyphenol* (**13**). ^1^H-NMR): *δ* 10.91 (s, 1H, OH), 8.52 (s, 1H, N=CH-Ar), 7.22 (d, 1H, *J* = 2.0 Hz), 7.12 (d, 1H, *J* = 2.0 Hz), 7.03--6.97 (m, 3H), 6.90 (d, 1H, *J* = 8.0 Hz), 3.84 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~), 3.76 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 153.2, 153.1, 150.1, 148.2, 146.4, 119.5, 118.2, 118.0, 117.1, 114.2, 113.4, 109.2, 56.1, 56.1, 55.8; Anal. Calcd for C~16~H~17~NO~4~, C = 66.89, H = 5.96, N = 4.88, Found C = 66.91, H = 5.95, N = 4.91; EI MS *m/z* (% rel. abund.): 287 (M^+^, 100), 255 (19), 137 (80), 122 (25).

*(E)-2-(((3,4-Dimethoxyphenyl)imino)methyl)-5-methoxyphenol* (**14**). ^1^H-NMR): *δ* 13.84 (s, 1H, OH), 8.88 (s, 1H, N=CH-Ar), 7.51 (d, 1H, *J* = 7.5 Hz), 7.09 (d, 1H, *J* = 2.0 Hz), 7.01 (d, 1H, *J* = 8.0 Hz), 6.96 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 6.57 (dd, 1H, *J* = 7.5, *J* = 2.0 Hz), 6.48 (dd, 1H, *J* = 2.0 Hz), 3.83 (s, 3H, OCH~3~), 3.81(s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 164.2, 162.0, 160.1, 1501, 148.2, 146.4, 133.2, 119.5, 114.2, 112.6, 109.1, 107.1, 103.3, 56.1, 56.1, 55.7; Anal. Calcd for C~16~H~17~NO~4~, C = 66.89, H = 5.96, N = 4.88, Found C = 66.90, H = 5.95, N = 4.92; EI MS *m/z* (% rel. abund.): 287 (M^+^, 100), 255 (30), 137 (85), 122 (19).

*(E)-3-(((3,4-Dimethoxyphenyl)imino)methyl)phenol* (**15**). ^1^H-NMR): *δ* 9.64 (s, 1H, OH), 8.57 (s, 1H, N=CH-Ar), 7.35 (d, 1H, *J* = 2.0 Hz), 7.31-7.30 (m, 2H), 7.31--7.30 (m, 2H), 6.98--6.97 (m, 1H), 6.92 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 6.86 (dd, 1H, *J* = 7.5, *J* = 2.0 Hz), 3.82 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR (DMSO-*d~6~*): *δ* 160.1, 158.4, 150.1, 148.2, 146.4, 138.6, 130.1, 121.6, 119.5, 118.1, 114.8, 114.3, 109.2, 56.1, 56.1; Anal. Calcd for C~15~H~15~NO~3~, C = 70.02, H = 5.88, N = 5.44, Found C = 70.03, H = 5.91, N = 5.42; EI MS *m/z* (% rel. abund.): 257 (M^+^, 100), 225 (21), 137 (60), 93 (20).

*(E)-N-(3,5-Dimethoxybenzylidene)-3,4-dimethoxyaniline* (**16**). ^1^H-NMR): *δ* 8.60 (s, 1H, N=CH-Ar), 7.10 (d, 2H, *J* = 2.0 Hz), 7.00 (d, 1H, *J* = 2.0 Hz), 6.98 (d, 1H, *J* = 8.0 Hz), 6.96 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 6.86 (t, 1H, *J* = 5.5 Hz), 3.82 (s, 9H, 3×OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 161.5, 161.5, 160.1, 150.1, 148.2, 146.4, 140.5, 119.5, 114.3, 109.2, 103.4, 103.4, 102.6, 56.1, 56.1, 55.8, 55.8; Anal. Calcd for C~17~H~19~NO~4~, C = 67.76, H = 6.36, N = 4.65, Found C = 67.77, H = 6.35, N = 4.66; EI MS *m/z* (% rel. abund.): 301 (M^+^, 40), 269 (45), 149 (21), 137 (100).

*(E)-3,4-Dimethoxy-N-(4-methoxybenzylidene)aniline* (**17**). ^1^H-NMR): *δ* 8.79 (s, 1H, N=CH-Ar), 8.10 (d, 2H, *J* = 8.5 Hz), 8.06 (d, 2H, *J* = 8.5 Hz),7.07 (d, 1H, *J* = 2.0 Hz), 7.02 (d, 1H, *J* = 8.0 Hz), 6.97 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.89 (s, 3H, OCH~3~), 3.83 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~); ^13^C-NMR (DMSO-*d~6~*): *δ* 162.7, 160.1, 150.1, 148.3, 146.4, 130.1, 130.1, 128.5, 119.5, 114.3, 114.3, 114.2, 109.2, 56.1, 56.1; Anal. Calcd for C~16~H~17~NO~3~, C = 70.83, H = 6.32, N = 5.16, Found C = 70.84, H = 6.33, N = 5.15; EI MS *m/z* (% rel. abund.): 271 (M^+^, 26), 151 (11), 138 (17), 137 (100).

*(E)-3,4-Dimethoxy-N-(3-methoxybenzylidene)aniline* (**18**). ^1^H-NMR): *δ* 8.46 (s, 1H, N=CH-Ar), 7.46 (d, 1H, *J* = 8.0 Hz), 7.43 (d, 1H, *J* = 7.5 Hz),7.31-7.24 (m, 2H), 7.04 (d, 1H, *J* = 8.0 Hz), 6.98 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 6.72 (d, 1H, *J* = 8.0 Hz), 3.84 (s, 3H, OCH~3~), 3.81 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.5, 160.1, 150.1, 148.3, 146.4, 138.1, 129.7, 121.4, 119.5, 116.4, 114.3, 111.3, 109.2, 56.1, 56.1; Anal. Calcd for C~16~H~17~NO~3~, C = 70.83, H = 6.32, N = 5.16, Found C = 70.82, H = 6.32, N = 5.15; EI MS *m/z* (% rel. abund.): 271 (M^+^, 100), 239 (20), 137 (60), 105 (24).

*(E)-N-(2-Chlorobenzylidene)-3,4-dimethoxyaniline* (**19**). ^1^H-NMR): *δ* 8.90 (s, 1H, N=CH-Ar), 8.16 (dd, 1H, *J* = 6.0, *J* = 2.0 Hz), 7.60 (dd, 1H, *J* = 6.0, *J* = 2.0 Hz), 7.56 (ddd, 1H, *J* = 6.0, *J* = 2.0, *J* = 2.0 Hz), 7.46 (t, 1H, *J* = 8.0 Hz), 7.02 (d, 1H, *J* = 7.5 Hz), 7.00 (s, 1H), 6.93 (dd, 1H, *J* = 6.0, *J* = 2.0 Hz), 3.84 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 157.1, 150.0, 148.2, 146.4, 133.8, 133.2, 132.2, 130.0, 127.1, 126.8, 119.5, 114.3, 109.2, 56.1, 56.1; Anal. Calcd for C~15~H~14~ClNO~2~, C = 65.34, H = 5.12, N = 5.08, Found C = 65.33, H = 5.13, N = 5.09; EI MS *m/z* (% rel. abund.): 277 (M+2, 31), 275 (M^+^, 100), 244 (15), 239 (17), 137 (40).

*(E)-N-(4-Bromo-3-fluorobenzylidene)-3,4-dimethoxyaniline* (**20**). ^1^H-NMR): *δ* 8.92 (s, 1H, N=CH-Ar), 7.90 (d, 1H, *J* = 8.0 Hz), 7.60 (dd, 1H, *J* = 7.0, *J* = 4.0 Hz), 7.20 (d, 1H, *J* = 8.0 Hz), 7.04 (d, 1H, *J* = 2.0 Hz), 6.98 (s, 1H), 6.93 (dd, 1H, *J* = 7.0, *J* = 2.0 Hz), 3.95 (s, 3H, OCH~3~), 3.83 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 165.4, 160.1, 148.2, 150.1, 146.4, 134.2, 133.2, 124.0, 119.5, 116.1, 114.2, 112.3, 109.2, 56.1, 56.1; Anal. C~15~H~13~BrFNO~2~, C = 53.27, H = 3.87, N = 4.14, Found C = 53.29, H = 3.89, N = 4.15; EI MS *m/z* (% rel. abund.): 339 (M+2, 46), 337 (M^+^, 49), 257 (25), 137 (100).

*(E)-Methyl 4-(((3,4-dimethoxyphenyl)imino)methyl)-3-nitrobenzoate* (**21**). ^1^H-NMR): *δ* 8.92 (s, 1H, N=CH-Ar), 8.70 (d, 1H, *J* = 2.0 Hz), 8.25 (dd, 1H, *J* = 7.0, *J* = 2.0 Hz), 8.21 (d, 1H, *J* = 8.0 Hz), 7.06 (d, 1H, *J* = 2.0 Hz), 7.01 (s, 1H), 6.96 (dd, 1H, *J* = 7.0, *J* = 2.0 Hz), 3.95 (s, 3H, OCH~3~), 3.83 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 165.8, 160.2, 150.1, 148.3, 147.6, 146.4, 136.1, 132.6, 131.6, 130.1, 123.4, 119.5, 114.2, 109.2, 56.1, 56.1, 52.1; Anal. Calcd for C~17~H~16~N~2~O~6~, C = 59.30, H = 4.68, N = 8.14, Found C = 59.31, H = 4.69, N = 8.15; EI MS *m/z* (% rel. abund.): 344 (M^+^, 100), 297 (22), 284 (30), 137 (100).

*(E)-3,4-Dimethoxy-N-(4-methylbenzylidene)aniline* (**22**). ^1^H-NMR): *δ* 8.61 (s, 1H, N=CH-Ar), 7.82 (d, 2H, *J* = 8.0 Hz), 7.33 (d, 2H, *J* = 8.5 Hz), 6.98 (d, 1H, *J* = 2.0 Hz), 6.97 (d, 1H, *J* = 8.0 Hz), 6.87 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.81 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~), 2.38 (s, 3H, CH~3~); ^13^C-NMR: *δ* 160.1, 150.1, 148.2, 146.4, 140.5, 133.2, 129.2, 129.2, 129.0, 129.0, 119.6, 114.3, 109.2, 56.1, 56.1, 21.2; Anal. Calcd for C~16~H~17~NO~2~, C = 75.27, H = 6.71, N = 5.49, Found C = 75.29, H = 6.72, N = 5.50; EI MS *m/z* (% rel. abund.): 255 (M^+^, 100), 223 (18), 137 (80), 103 (28).

*(E)-3,4-Dimethoxy-N-(pyridin-4-ylmethylene)aniline* (**23**). ^1^H-NMR): *δ* 9.02 (s, 1H, N=CH-Ar), 8.61 (d, 2H, *J* = 8.0 Hz), 7.91 (d, 2H, *J* = 8.5 Hz), 7.03 (d, 1H, *J* = 2.0 Hz), 6.99 (d, 1H, *J* = 8.0 Hz), 6.91 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.84 (s, 3H, OCH~3~), 3.79 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 160.1, 150.2, 149.2, 148.3, 149.2, 144.2, 142.1, 120.3, 120.3, 119.5, 114.2, 109.3, 56.1, 56.1; Anal. Calcd for C~14~H~14~N~2~O~2~, C = 69.41, H = 5.82, N = 11.56, Found C = 69.40, H = 5.83, N = 11.57; EI MS *m/z* (% rel. abund.): 242 (M^+^, 100), 210 (20), 137 (50), 91 (50).

*(E)-N-(4-Fluorobenzylidene)-3,4-dimethoxyaniline* (**24**). ^1^H-NMR): *δ* 8.67 (s, 1H, N=CH-Ar), 8.00 (dd, 2H, *J* = 8.5, *J* = 4.0 Hz), 7.91 (t, 2H, *J* = 8.5 Hz), 7.00 (d, 1H, *J* = 2.0 Hz), 6.98 (d, 1H, *J* = 8.0 Hz), 6.94 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.82 (s, 3H, OCH~3~), 3.78 (s, 3H, OCH~3~); ^13^C-NMR: *δ* 165.1, 160.1, 150.2, 148.3, 146.3, 132.1, 130.7, 130.7, 119.4, 115.5, 115.5, 114.3, 109.2, 56.1, 56.1; Anal. Calcd for C~15~H~14~FNO~2~, C = 69.49, H = 5.44, N = 5.40, Found C = 69.48, H = 5.43, N = 5.42; EI MS *m/z* (% rel. abund.): 259 (M^+^, 100), 227 (11), 137 (100), 95 (20).

*(E)-3,4-Dimethoxy-N-(4-nitrobenzylidene)aniline* (**25**). ^1^H-NMR): *δ* 8.88 (s, 1H, N=CH-Ar), 8.37 (d, 2H, *J* = 8.0 Hz), 8.18 (d, 2H, *J* = 8.5 Hz), 7.11 (d, 1H, *J* = 2.0 Hz), 7.03 (d, 1H, *J* = 8.0 Hz), 7.01 (dd, 1H, *J* = 8.0, *J* = 2.0 Hz), 3.84 (s, 3H, OCH~3~), 3.80 (s, 3H, OCH~3~), 2.38 (s, 3H, CH~3~); ^13^C-NMR: *δ* 160.1, 150.3, 150.1, 148.2, 146.4, 142.4, 127.6, 127.6, 124.1, 124.1, 119.5, 114.2, 109.2 Anal. Calcd for C~15~H~14~N~2~O~4~, C = 62.93, H = 4.93, N = 9.79, Found C = 62.94, H = 4.92, N = 9.80; EI MS *m/z* (% rel. abund.): 286 (M^+^, 100), 254 (17), 239 (20), 137 (100), 122 (16).

3.5. Theoretical Calculations
-----------------------------

The optimization of the synthesized Schiff bases were performed at the B3LYP/6-311++G(d,p) level of theory \[[@B59-molecules-19-08414]\]. The minima were confirmed by vibrational frequency analysis (*i.e.*, no imaginary frequency were found). All theoretical calculations were carried out using Gaussian09 package \[[@B60-molecules-19-08414]\].

4. Conclusions
==============

In conclusion, compounds having hydroxyl groups at suitable places as well as number of hydroxyl groups play a key role in the antioxidant activity. Three crystal structures along with its theoretical calculations are also reported with experimental value well correlated.
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